Henlius Kicks Off Trial For Darzalex Biosimilar
Chinese Firm Begins Phase I Study For HLX15 Daratumumab Candidate
Executive Summary
Shanghai Henlius Biotech has announced the start of Phase I trials for its HLX15 proposed daratumumab biosimilar rival to Darzalex. But the Chinese firm is not the only developer chasing the $8bn brand.
You may also be interested in...
Xbrane Biopharma Swells In Oncology With Keytruda And Darzalex Projects
Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
Medicines Patent Pool Welcomes WHO’s Updated Essential Medicines List
The Medicines Patent Pool has welcomed the WHO’s updated essential medicines list that includes four medicines already licensed to the MPP, of which two were developed through MPP licensees. The WHO’s updated list includes SGLT2 inhibitors – oral medications used to lower blood glucose levels – for which the MPP and the International Diabetes Federation have committed to improve affordable access in low- and middle-income countries.
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.